Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Viking Therapeutics (VKTX) dropped 18.6% in July as the company's $96 million quarterly cash burn and a planned $500 million equity offering weighed on investor sentiment. The dilution concerns overshadowed progress on VK2735, the company's weight-loss drug candidate advancing through phase 3 trials.

Despite the July selloff, Viking maintains cash reserves sufficient to fund operations through 2028, aligning runway with the expected timeline for phase 3 trial results. The company is positioning itself in the competitive weight-loss drug market, where VK2735 competes against established players and other pipeline candidates.

The equity offering announcement triggered the decline as shareholders priced in potential ownership dilution. Viking's $96 million quarterly burn rate underscores the capital intensity of late-stage clinical development, though management's 2028 cash runway projection suggests the planned raise should cover anticipated expenses through trial completion.